"Metastatic Pancreatic Cancer" trang 1 - tải miễn phí từ tailieunhanh
Circulating CD8+CD122+ T cells as a prognostic indicator of pancreatic cancer

Circulating CD8+CD122+ T cells as a prognostic indicator of pancreatic cancer
14    2    1
Serum gamma-glutamyltransferase and the overall survival of metastatic pancreatic cancer

Serum gamma-glutamyltransferase and the overall survival of metastatic pancreatic cancer
7    102    0
Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: A retrospective study

Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: A retrospective study
9    116    0
Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcioma: A single center experience

Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcioma: A single center experience
7    72    1
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): From clinical trials to clinical practice

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): From clinical trials to clinical practice
8    64    1
Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: A subanalysis from a phase 3 trial (MPACT)

Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: A subanalysis from a phase 3 trial (MPACT)
10    64    1
Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: A phase II study

Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: A phase II study
7    78    1
A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol

A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol
11    68    1
Survival in overweight patients with advanced pancreatic carcinoma: A multicentre cohort study

Survival in overweight patients with advanced pancreatic carcinoma: A multicentre cohort study
7    64    1
Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: A retrospective observational study

Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: A retrospective observational study
9    44    1
E-cadherin might be a stage-dependent modulator in aggressiveness in pancreatic cancer cells

E-cadherin might be a stage-dependent modulator in aggressiveness in pancreatic cancer cells
8    45    1
Prognostic factors for survival with nabpaclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: The ANICE-PaC study

Prognostic factors for survival with nabpaclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: The ANICE-PaC study
11    68    1
Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: A prospective cohort study

Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: A prospective cohort study
9    82    0
Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: A real world study

Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: A real world study
8    1    1
Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nabpaclitaxel therapy in metastatic pancreatic cancer

Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nabpaclitaxel therapy in metastatic pancreatic cancer
9    77    0
Early venous thromboembolism at the beginning of palliative chemotherapy is a poor prognostic factor in patients with metastatic pancreatic cancer: A retrospective study

Early venous thromboembolism at the beginning of palliative chemotherapy is a poor prognostic factor in patients with metastatic pancreatic cancer: A retrospective study
10    46    1
FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study
8    52    1
Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer

Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer
12    63    1
CARDIOMYOPATHIES – FROM BASIC RESEARCH TO CLINICAL MANAGEMENT

CARDIOMYOPATHIES – FROM BASIC RESEARCH TO CLINICAL MANAGEMENT

814    56    0
Oral health behaviour, conditions and care among dentate elderly patients in Lithuania: preventive aspects

Oral health behaviour, conditions and care among dentate elderly patients in Lithuania: preventive aspects

72    81    0